Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9Y5F7
UPID:
PCDGL_HUMAN
Alternative names:
-
Alternative UPACC:
Q9Y5F7; Q495T2; Q9Y5C3
Background:
Protocadherin gamma-C4, a potential calcium-dependent cell-adhesion protein, plays a crucial role in the establishment and maintenance of specific neuronal connections in the brain. Its involvement in neurodevelopment underscores its importance in cognitive and physical development.
Therapeutic significance:
Linked to the neurodevelopmental disorder with poor growth and skeletal anomalies, Protocadherin gamma-C4's study offers insights into therapeutic strategies targeting genetic variants affecting this protein, potentially improving patient outcomes.